Research programme: high molecular weight GPBP therapeutics- Fibrostatin

Drug Profile

Research programme: high molecular weight GPBP therapeutics- Fibrostatin

Alternative Names: FSM 26; FST 12; GPBP inhibitor; GPBP-Mab; T-12

Latest Information Update: 02 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator FibroStatin
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Protein serine threonine kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Diabetes mellitus; Idiopathic pulmonary fibrosis; Kidney disorders; Non-small cell lung cancer

Most Recent Events

  • 02 Nov 2016 FibroStatin has patent protection for FST 12 in USA, Europe, Japan and China (FibroStatin website, November 2016)
  • 01 May 2016 Preclinical trials in Breast cancer in Spain (unspecified route)
  • 01 May 2016 Preclinical trials in Diabetes mellitus in Spain (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top